GlassScriptPhysician profile
Michael Evan Sala
NPI 1891836722
$3,514.90
in general payments reported to CMS, 2019-2025
22 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $158 · 2021: $440 · 2022: $119 · 2023: $365 · 2024: $361 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $669.07 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $457.90 | 2023-2025 | Syfovre |
| Allergan, INC. | $383.97 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $323.61 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $285.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $156.81 | 2019-2023 | |
| Dompe US, INC. | $153.10 | 2021-2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $152.17 | 2019-2021 | |
| Omeros Corporation | $138.76 | 2019 | |
| Bausch & Lomb Americas INC. | $126.61 | 2022-2024 | Xiidra, Miebo |
| Harrow Eye, LLC | $125.00 | 2025 | Triesence, Iheezo |
| Sight Sciences, INC. | $120.24 | 2025 | Omni Surgical System |
| Alcon Vision LLC | $117.14 | 2019-2025 | Hydrus Microstent, Unity |
| Abbvie INC. | $74.53 | 2023-2025 | Lumigan, Alphagan P |
| Amgen INC. | $73.18 | 2024-2025 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $36.41 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $26.19 | 2020 | |
| Ocular Therapeutix, INC. | $24.19 | 2025 | Dextenza |
| Oyster Point Pharma, INC. | $23.39 | 2023 | Tyrvaya |
| Thea Pharma INC. | $18.53 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $16.24 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.